Skip to main content
NewslettersWatchlist

Redhill Biophrma ADR(RDHL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.4600
Day High0.4830
Open:0.4700
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
PR Newswire
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
PR Newswire
RedHill Announces FDA sNDA Approval for Talicia®
PR Newswire
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
PR Newswire
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.
PR Newswire
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
PR Newswire
RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise
PR Newswire
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds
PR Newswire
RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights
PR Newswire
RedHill Provides R&D Update
PR Newswire
RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
PR Newswire
RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting
PR Newswire
RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights
PR Newswire
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
PR Newswire
RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering
PR Newswire
RedHill Biopharma Announces $6 Million Registered Direct Offering
PR Newswire
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
PR Newswire
RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor
ACCESSWIRE
RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development
ACCESSWIRE
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
PR Newswire
RedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for Movantik®
ACCESSWIRE
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL)
PR Newswire
RedHill Biopharma Closes $8.0 Million Underwritten Public Offering
PR Newswire
RedHill's Aemcolo® Granted FDA QIDP 5-Year Exclusivity Extension
PR Newswire
RedHill Biopharma Announces Proposed Public Offering
PR Newswire
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
PR Newswire
RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published
PR Newswire
RedHill Biopharma Reaches Agreement in Principle with HCR to Extinguish All Debt Obligations in Exchange for Movantik®
PR Newswire
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
PR Newswire
RedHill Presents New Talicia® Data Analyses at Obesity Week 2022
PR Newswire
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
PR Newswire
RedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific Conferences
PR Newswire
RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22

Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company, focused on gastrointestinal and infectious diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment is based in Raleigh, NC, and covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.